New Tech Aims to Help Pet Owners Detect Pain During Animal Pain Awareness Month
/
Date19 Sep 2016
BURLINGTON, Mass., Sept. 19, 2016 (GLOBE NEWSWIRE) — via PRWEB – September is Animal Pain Awareness Month and PetPace, the producer of a leading smart... Read More →
CORRECTING and REPLACING – CoLucid Pharmaceuticals Provides Interim Update on GLADIATOR
/
Date19 Sep 2016
1,155 patients have been randomized in GLADIATOR, with a retention rate of 74% of those patients 100 mg and 200 mg doses of lasmiditan collectively... Read More →
Fibrocell Completes Enrollment in NC1+ Cohort of Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
/
Date19 Sep 2016
EXTON, Pa., Sept. 19, 2016 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ:FCSC) today announced that two additional adult subjects were enrolled in the Phase I/II... Read More →
Home Healthcare Market projected to grow at a CAGR of 9.40%, to reach USD 391.41 billion by 2021 – Zion Market Research
/
Date19 Sep 2016
Sarasota, FL, Sept. 19, 2016 (GLOBE NEWSWIRE) — Zion Research has published a new report titled “Global Home Healthcare Market (Diagnostics and Monitoring Devices, Therapeutic... Read More →
Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy
/
Date19 Sep 2016
–Phase 2b STOP-HE Enrollment Surpasses 205 Patients; On Track to Complete in Q4 2016– PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2016... Read More →
Catalyst Pharmaceuticals Announces Publication of CPP-115 Clinical Efficacy Data for Infantile Spasms in Epilepsy & Behavior Case Reports
/
Date19 Sep 2016
CORAL GABLES, Fla., Sept. 19, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with... Read More →
Adaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR® T-cell Therapies Towards Commercialization
/
Date19 Sep 2016
PHILADELPHIA and OXFORD, United Kingdom, Sept. 19, 2016 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced... Read More →
CoLucid Pharmaceuticals Provides Interim Update on GLADIATOR
/
Date19 Sep 2016
1,155 patients have been randomized in GLADIATOR, with a retention rate of 74% of those patients 100 mg and 200 mg doses of lasmiditan collectively... Read More →
Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients
/
Date19 Sep 2016
SAN DIEGO and TOKYO, Sept. 19, 2016 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) and Astellas Pharma Inc. (TOKYO:4503) today announced topline results from a randomized,... Read More →
Gemphire Therapeutics Announces Publication of Phase 2 Data for Gemcabene in the Journal of Clinical Lipidology
/
Date19 Sep 2016
LIVONIA, Mich., Sept. 19, 2016 (GLOBE NEWSWIRE) — Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment... Read More →